- For Future Medical Breakthroughs, We Must Rebuild Research Lost to COVID (April 2021) - In this op-ed in The Hill, Dean Rothman and his co-authors argue that the federal government must do all it can to support academic medical research.
Paul B. Rothman: Leading the Change
Paul B. Rothman is the dean of the medical faculty for the Johns Hopkins University School of Medicine and the CEO of Johns Hopkins Medicine. Over his tenure, he has focused on ensuring that JHM provides the best care possible for patients and their families, that our clinicians, researchers, staff, students have what they need to succeed, and that we work closely to support our communities and the world at large. This has never been more true than during the pandemic. Below, find out more about these varied efforts.
Find out more about how Johns Hopkins is meeting the challenge of the pandemic.
Talking with CDC Director Rochelle Walensky
For the latest Johns Hopkins Health Policy Forum, Dean Rothman talks with Dr. Walensky about the pandemic, clinician burnout, health equity – and her memories of being a medical student at Hopkins. (May 2021)
Delving into Vaccines
Dean Rothman and William Moss, executive director of Hopkins’ International Vaccine Access Center, discuss vaccine safety for children and pregnant women, what the future may hold, and other topics. (May 2021)
Understanding More about Variants
How will the variants change the pandemic’s trajectory? Dean Rothman speaks with Heba Mostafa, director of the molecular virology laboratory at Johns Hopkins Hospital. Dr. Mostafa is helping to Hopkins’ testing efforts. (March 2021)
COVID-19 Insights From Dean Rothman
- Geared Up for a Marathon (September 2020) - In his quarterly column, Dean Rothman discusses the institution’s efforts to treat Covid patients as well as patients with other illnesses, while maintaining adequate safety for all.
Dean Rothman and other Hopkins leaders discuss efforts to improve the institution and its work.
The State of Johns Hopkins Medicine 2021 Address - November 2021
Paul B. Rothman, dean of the medical faculty and CEO of Johns Hopkins Medicine, highlights the commitment of JHM’s faculty, staff and learners during the past year, and our achievements in patient care, education, innovation and discovery.
Howard County General Hospital, November 2021
Dean Rothman, Kevin Sowers and Shafeeq Ahmed, president of Howard County General Hospital, discuss the vaccine requirement, the pandemic, and new developments at HCGH.
Bayview Medical Center Town Hall, October 2021
Dean Rothman, Kevin Sowers and Bayview president Richard Bennett discuss the pandemic, staffing across the health system, as well as latest developments at Bayview Medical Center.
National Capital Region Town Hall, October 2021
Dean Rothman, Kevin Sowers and JHM’s National Capital Region leaders discuss the pandemic, as well as JHM’s plans to grow in the NCR.
Johns Hopkins Medicine Town Hall, September 2021
Dean Rothman, Kevin Sowers discuss the COVID vaccine requirement, recruitment and retention strategies, and how to foster well-being for our staff.
Dr. Paul Rothman is the dean of the medical faculty for the Johns Hopkins University School of Medicine and chief executive officer of Johns Hopkins Medicine, a $10 billion academic medical enterprise and health system with a global reach. As dean/CEO, Dr. Rothman oversees both the Johns Hopkins Health System and the school of medicine.
A rheumatologist and molecular immunologist, he came to Johns Hopkins in 2012, after serving as dean of the Carver College of Medicine at the University of Iowa. Previously, he served as head of internal medicine at the University of Iowa, and prior to that, as vice chairman for research and founding director of the Division of Pulmonary, Allergy and Critical Care Medicine at Columbia University College of Physicians and Surgeons, where he joined the faculty in 1990.
A 1980 Phi Beta Kappa graduate of the Massachusetts Institute of Technology, Rothman received his Medical degree from Yale University in 1984, earning a place in the Alpha Omega Alpha Honor Medical Society. He then trained at New York-Presbyterian/Columbia University Irving Medical Center in internal medicine and rheumatology and accepted a postdoctoral fellowship at Columbia University prior to joining its medical school faculty.
Rothman's research focused on immune system molecules, known as cytokines. Specifically, he investigated the role these molecules play in the normal development of blood cells, as well as the abnormal development of these blood cells that leads to leukemia.
Dr. Rothman is a member of the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Society for Clinical Investigation. He has served as president of the Association of American Physicians and the Society of Medical Administrators, and was elected as a Fellow of the American Association for the Advancement of Sciences.
Dr. Rothman is a member of the Merck board of directors and receives compensation in the form of income and stock. Dr. Rothman also is a member of the board of directors of the King Faisal Specialty Hospital, for which he receives compensation in the form of income. To submit concerns related to this arrangement, please contact: email@example.com.